Navigation Links
CardioDx to Present at the 12th Annual Needham Healthcare Conference
Date:4/23/2013

PALO ALTO, Calif., April 23, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 9:40 AM ET at the Westin Grand Central Hotel in New York. David Levison , the company's President and Chief Executive Officer, will provide an overview of CardioDx and Corus® CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD).

(Logo: http://photos.prnewswire.com/prnh/20130219/MM60898)

CardioDx recently announced the publication of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association. Results of the prospective, multi-center U.S. study showed that Corus CAD outperformed traditional stress testing with myocardial perfusion imaging (MPI), demonstrating high accuracy with both a higher sensitivity (89 percent vs. 27 percent) and higher negative predictive value (96 percent vs. 88 percent) than MPI for assessing the presence of obstructive CAD. 

With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms are due to obstructive CAD, enabling many patients to avoid unnecessary noninvasive and invasive cardiac procedures an
'/>"/>

SOURCE CardioDx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CardioDx to Present at Cowen and Company 33rd Annual Healthcare Conference
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
9. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Phreesia, the patient check-in company, today ... health records (EHR) software and solutions, has been ... partnership, medical practices nationwide that use both SOAPware ... seamless patient check-in experience. The automated interface between ...
... 18, 2011 Ohio-based AdCare Health Systems, Inc. ... Remedi SeniorCare®, one of the nation,s largest institutional ... services for AdCare,s facilities  that deliver long-term care ... Remedi pharmacy services will include pharmacist ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions 2AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions 3
(Date:4/22/2014)... computational tool developed at the University of Utah (U ... mutations in three separate cases, U of U researchers ... The American Journal of Human Genetics . The ... undiagnosed illnesses and unknown gene mutations by analyzing the ... for genes are made, in individual patients and small ...
(Date:4/22/2014)... cell lung cancer are 70 years of age or ... are not well represented in clinical trials. Therefore, the ... reach evidence based clinical recommendations. , In 2010, the ... Cancer Group along with the International Society for Geriatric ... for elderly patients with non-small cell lung cancer (NSCLC), ...
(Date:4/22/2014)... -- When mothers are exposed to trauma, illness, alcohol ... single molecular trigger in brain cells that can go ... disorder and some forms of autism. , Until now, ... impacted the cells of a developing brain. Past studies ... to alcohol or drug abuse or she experiences some ...
(Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
(Date:4/22/2014)... on results of a clinical trial led by ... Drug Administration (FDA) approved a molecularly targeted drug ... has progressed after standard chemotherapy has failed. , ... announced by the manufacturer, Lilly Oncology, of Indianapolis. ... it will be sold under the name Cyramza, ...
Breaking Medicine News(10 mins):Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2
... lead character smokes is not as effective a method as ... the appeal of smoking to , are non-smokers. ... the June issue of the journal Tobacco Control. ... whom were current smokers, aged 12-24 years in Australia, over ...
... found that diabetes is associated with decreases in life expectancy, ... ,The study, published in Archives of Internal Medicine, ... with diabetes at age 50 and older appear not to ... without cardiovascular disease, than individuals without diabetes. ,Globalization ...
... Just a short walk from some of Tokyo's most chic ... for long, if the government gets its way . In ... baskets loaded with their fresh catch at Tsukiji market, minutes ... luxury shops and corporate headquarters. The world's largest ...
... disease in monkeys with the help of human stem cell ... in the Proceedings of the National Academy of Sciences, the ... and grew them into large numbers in the laboratory. ... of monkeys with a severe form of chemically induced Parkinson's ...
... ballet shoe are booming in Britain, where the latest unusual ... environment . Since 2000, Vic Fearn and Company have been ... Coffins". The firm recently expanded their range to ... from the clients," said John Gill, head of the Nottingham, ...
... is dumped in Urali Devachi, about 25 kilometers from the ... villagers . ,Urali Devachi village has been turned into ... the citys nearly five million plus population. ,The ... to Urali Devachi, located on Pune-Saswad road, in 1999. ...
Cached Medicine News:Health News:Diabetes Reduces Life Expectancy, Increases Heart Disease Risk 2Health News:Traders Smell Something Fishy in Tokyo Market Move 2Health News:Traders Smell Something Fishy in Tokyo Market Move 3Health News:To Die For: Rolls-Royce and 'green' Coffins at British Funerals 2
Inquire...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
... Mo Bio Vortex Adapter in conjunction with the ... Using the Mo Bio Vortex Adapter is ... Fast Prep machines which offer the same technology. ... centrifuge tubes at one time and will fit ...
Medicine Products: